基本信息
浏览量:3
职业迁徙
个人简介
His research interests center on the development of a fundamental understanding of the mechanisms–transformations involved during the formation of drug nanoparticles via top-down and bottom-up approaches, nanocomposite microparticles, and amorphous solid dispersions. His research group uses experimentation coupled with population balance modeling (PBM), discrete element modeling (DEM), and microhydrodynamic modeling in a unique multi-scale approach to elucidate complex non-linear rate processes. Prior to this academic position, Dr. Bilgili worked as Principal Development Engineer within R&D and Pharmaceutical Commercialization Technology Department at Merck & Co., Inc during 2004–2009. Before Merck years, he had worked as a post-doctoral research associate at the Particle Engineering Research Center, University of Florida.
研究兴趣
论文共 123 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Powder technology (2024): 119760-119760
Powdersno. 2 (2024): 190-201
PHARMACEUTICSno. 3 (2024)
Donald J. Clancy,Gulenay Guner,Sayantan Chattoraj,Helen Yao, M. Connor Faith, Zahra Salahshoor, Kailey N. Martin,Ecevit Bilgili
Pharmaceuticsno. 3 (2024): 394-394
Ecevit Bilgili, Sadegh Poozesh
Advanced powder technologyno. 10 (2023): 104171-104171
Powder technology (2023): 118737-118737
PHARMACEUTICSno. 9 (2023): 2213-2213
Powder technology (2023): 118454-118454
加载更多
作者统计
#Papers: 123
#Citation: 3438
H-Index: 34
G-Index: 53
Sociability: 5
Diversity: 0
Activity: 1
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn